TAmiRNA � osteomiR®

TAmiRNA is a biotechnology company specializing in the discovery and development of microRNA biomarkers. MicroRNA Biomarker Discovery and Development: TAmiRNA operates a research and development laboratory equipped for high-throughput screening of microRNA transcript levels in various biological samples. They have protocols for isolating microvesicles and RNA, using locked-nucleic-acid (LNA) based qPCR and next-generation sequencing technologies. Collaborations with Grillari Labs and Evercyte support testing the biological function of microRNAs for diagnosis, prognosis, treatment monitoring, and drug development​​. Among their leading biomarkers is OsteomiR® Test: This test identifies circulating microRNA biomarkers to predict fracture risk in post-menopausal women and aged men. It aims to facilitate early diagnosis and treatment of osteoporosis to prevent severe fractures. Future Expansion: TAmiRNA is also developing early-stage projects in liver disease, cancer, and aging, and is actively seeking to expand its product and technology pipeline through in-licensing of intellectual property from academia and industry​​.